Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article from MedicalXPress referenced a study published in the June 2024 issue of The American Journal of Managed Care® (AJMC®). The article, “Deductible Double Jeopardy: Patients May Pay More Out of Pocket When Pregnancy Crosses 2 Years,” shows that greater out-of-pocket spending occurred when pregnant patients faced their cost-sharing limits twice within an episode of maternity care, which persists through 3 calendar years of out-of-pocket spending.
An article from Gilbert Sun News referenced an article published in the October 2021 issue of AJMC. The piece, “Providing Patients With Cancer Access to Affordable Housing During Treatment,” discussed the difficulties in patients traveling for their cancer treatment and how affordable housing for the patient could be beneficial in the long term.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More